The problems with today's pharmaceutical business-an outsider's view

被引：74

作者：

Kessel, Mark ^{[1
]}

机构：

[1] Symphony Capital, New York, NY USA

来源：

NATURE BIOTECHNOLOGY | 2011年 / 29卷 / 01期

关键词：

D O I：

10.1038/nbt.1748

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The pharmaceutical industry must devote greater resources, investment and effort to address its anemic drug pipeline in the long term, rather than focusing on its bottom line in the near term.

引用

页码：27 / 33

页数：7

共 9 条

[1]

[Anonymous], 2010, BIOCENTURY EXTR 0616, P3

[2]

[Anonymous], CHANGING PHARM INNOV

[3]

[Anonymous], 2010, RESULTS ANNOUNCEMENT

[4]

Ernst & Young, 2009, BORD GLOB BIOT REP

[5] Drug giants turn their backs on RNA interference [J].

Ledford, Heidi .

NATURE, 2010, 468 (7323) :487-487

[6]

Oliver Wyman, 2008, LICENSING WIN

[7]

PricewaterhouseCoopers, 2008, PHARM 2020 VIRT R D

[8] Pfizer explores rare disease path [J].

Shaffer, Catherine .

NATURE BIOTECHNOLOGY, 2010, 28 (09) :881-882

[9]

2010, FINANCIAL TIMES 0512

← 1 →